These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2187525)

  • 1. Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma.
    Masding J; Sarkar TK; White WF; Barley VL; Chawla SL; Boesen E; Rostom AY; Menday AP
    Br J Obstet Gynaecol; 1990 Apr; 97(4):342-51. PubMed ID: 2187525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy of ovarian carcinoma with cisplatinum and treosulfan--a phase II study.
    Duncan ID; Clayton LA
    Br J Obstet Gynaecol; 1985 Jul; 92(7):762-7. PubMed ID: 4040389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treosulfan in the treatment of advanced ovarian cancer: a randomised co-operative multicentre phase III-study.
    Breitbach GP; Meden H; Schmid H; Kühn W; Sass G; Schach S; Schmidt-Rohde P; Bastert G;
    Anticancer Res; 2002; 22(5):2923-32. PubMed ID: 12530019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO).
    Sehouli J; Tomè O; Dimitrova D; Camara O; Runnebaum IB; Tessen HW; Rautenberg B; Chekerov R; Muallem MZ; Lux MP; Trarbach T; Gitsch G
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):541-550. PubMed ID: 27896440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional Study.
    Chekerov R; Kaltenecker G; Reichert D; Göhler T; Klare P; Oskay-Özcelik G; Sauer U; Wischnik A; Vehling-Kaiser U; Becker M; Hutzschenreuter U; Ammon A; Heidrich-Lorsbach E; Sehouli J
    Anticancer Res; 2015 Dec; 35(12):6869-75. PubMed ID: 26637909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer.
    du BA; Meier W; Lück HJ; Emon G; Moebus V; Schroeder W; Costa S; Bauknecht T; Olbricht S; Jackisch C; Richter B; Wagner U
    Ann Oncol; 2002 Feb; 13(2):251-7. PubMed ID: 11886002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity.
    Meden H; Wittkop Y; Kuhn W
    Anticancer Res; 1997; 17(3C):2221-3. PubMed ID: 9216692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial.
    Neuber K; Reinhold U; Deutschmann A; Pföhler C; Mohr P; Pichlmeier U; Baumgart J; Hauschild A
    Melanoma Res; 2003 Feb; 13(1):81-5. PubMed ID: 12569289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug resistance in ovarian cancer - the role of p53.
    Petty R; Evans A; Duncan I; Kurbacher C; Cree I
    Pathol Oncol Res; 1998; 4(2):97-102. PubMed ID: 9654593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG).
    Reed NS; Poole CJ; Coleman R; Parkin D; Graham JD; Kaye SB; Ostrowski J; Duncan I; Paul J; Hay A;
    Eur J Cancer; 2006 Jan; 42(2):179-85. PubMed ID: 16337372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
    Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M
    Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral treosulfan as second-line treatment in platinum-resistant ovarian cancer: a phase II study. The Danish Ovarian Cancer Study Group.
    Keldsen N; Madsen EL; Havsteen H; Kamby C; Laursen L; Sandberg E
    Gynecol Oncol; 1998 May; 69(2):100-2. PubMed ID: 9625618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, randomized, national trial for treatment of ovarian cancer: the role of chemotherapy and external irradiation.
    Grönroos M; Nieminen U; Kauppila A; Kauppila O; Saksela E; Väyrynen M
    Eur J Obstet Gynecol Reprod Biol; 1984 Apr; 17(1):33-42. PubMed ID: 6376194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
    Alberts DS; Liu PY; Hannigan EV; O'Toole R; Williams SD; Young JA; Franklin EW; Clarke-Pearson DL; Malviya VK; DuBeshter B
    N Engl J Med; 1996 Dec; 335(26):1950-5. PubMed ID: 8960474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treosulfan in platinum-resistant ovarian cancer.
    Olesen KD; Larsen ATR; Jensen LH; Steffensen KD; Søndergaard SR
    Int J Gynecol Cancer; 2021 Jul; 31(7):1045-1051. PubMed ID: 34006568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
    Armstrong DK; Bundy B; Wenzel L; Huang HQ; Baergen R; Lele S; Copeland LJ; Walker JL; Burger RA;
    N Engl J Med; 2006 Jan; 354(1):34-43. PubMed ID: 16394300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer].
    Sevelda P; Kurz C; Obermair A; Vavra N; Breitenecker G; Czerwenka K; Dittrich C; Salzer H
    Wien Klin Wochenschr; 1993; 105(24):732-6. PubMed ID: 8116312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.